Minor cardiac troponin t release in patients undergoing coronary artery bypass graft surgery on a beating heart

2000 ◽  
Vol 14 (2) ◽  
pp. 151-155 ◽  
Author(s):  
Toshiya Shiga ◽  
Katsuyuki Terajima ◽  
Junya Matsumura ◽  
Atsuhiro Sakamoto ◽  
Ryo Ogawa
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ali Vasheghani Farahani ◽  
Abbas Salehi Omran ◽  
Kyomars Abbasi ◽  
Ali Gholamrezaei ◽  
Pejman Mansouri ◽  
...  

Circulation ◽  
2009 ◽  
Vol 120 (10) ◽  
pp. 843-850 ◽  
Author(s):  
Asim A. Mohammed ◽  
Arvind K. Agnihotri ◽  
Roland R.J. van Kimmenade ◽  
Abelardo Martinez-Rumayor ◽  
Sandy M. Green ◽  
...  

1999 ◽  
Vol 68 (4) ◽  
pp. 1558-1561 ◽  
Author(s):  
Gijs G Geskes ◽  
André L Dekker ◽  
Frederik H van der Veen ◽  
Audrey A Cramers ◽  
Jos G Maessen ◽  
...  

2017 ◽  
Vol 127 (6) ◽  
pp. 918-933 ◽  
Author(s):  

Abstract Background Ischemic myocardial damage accompanying coronary artery bypass graft surgery remains a clinical challenge. We investigated whether xenon anesthesia could limit myocardial damage in coronary artery bypass graft surgery patients, as has been reported for animal ischemia models. Methods In 17 university hospitals in France, Germany, Italy, and The Netherlands, low-risk elective, on-pump coronary artery bypass graft surgery patients were randomized to receive xenon, sevoflurane, or propofol-based total intravenous anesthesia for anesthesia maintenance. The primary outcome was the cardiac troponin I concentration in the blood 24 h postsurgery. The noninferiority margin for the mean difference in cardiac troponin I release between the xenon and sevoflurane groups was less than 0.15 ng/ml. Secondary outcomes were the safety and feasibility of xenon anesthesia. Results The first patient included at each center received xenon anesthesia for practical reasons. For all other patients, anesthesia maintenance was randomized (intention-to-treat: n = 492; per-protocol/without major protocol deviation: n = 446). Median 24-h postoperative cardiac troponin I concentrations (ng/ml [interquartile range]) were 1.14 [0.76 to 2.10] with xenon, 1.30 [0.78 to 2.67] with sevoflurane, and 1.48 [0.94 to 2.78] with total intravenous anesthesia [per-protocol]). The mean difference in cardiac troponin I release between xenon and sevoflurane was −0.09 ng/ml (95% CI, −0.30 to 0.11; per-protocol: P = 0.02). Postoperative cardiac troponin I release was significantly less with xenon than with total intravenous anesthesia (intention-to-treat: P = 0.05; per-protocol: P = 0.02). Perioperative variables and postoperative outcomes were comparable across all groups, with no safety concerns. Conclusions In postoperative cardiac troponin I release, xenon was noninferior to sevoflurane in low-risk, on-pump coronary artery bypass graft surgery patients. Only with xenon was cardiac troponin I release less than with total intravenous anesthesia. Xenon anesthesia appeared safe and feasible.


Sign in / Sign up

Export Citation Format

Share Document